Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | DNM2 | P50570 | 10/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.32 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ALPG | P10696 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13116703 | 0.67 | HSD17B10 (0.38) | CYP2C19DNM2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL932573 | 0.62 | CYP2C19 (0.53) | CYP2C19DNM2HRH3HRH4GAA | |
| SCHEMBL18239960 | 0.62 | DNM2 (0.47) | CYP2C19DNM2HRH3 | |
| SCHEMBL11378396 | 0.59 | ALDH1A1 (0.49) | CYP2C19DNM2HRH3HRH4GAA | |
| SCHEMBL933805 | 0.58 | CYP2C19 (0.44) | CYP2C19DNM2HRH3HRH4GAA | |
| SCHEMBL3561186 | 0.57 | — | — | |
| SCHEMBL5596454 | 0.57 | CYP2C19 (0.44) | CYP2C19DNM2HRH3HRH4GAA | |
| SCHEMBL3058517 | 0.57 | POLB (0.58) | CSNK2A2CSNK2BCSNK2A1HRH3HSD17B10 | |
| SCHEMBL24831580 | 0.56 | DNM2 (0.43) | DNM2PRMT3CARM1PRMT6PRMT1 | |
| SCHEMBL5622381 | 0.56 | ALDH1A1 (0.62) | CYP2C19DNM2HRH3HRH4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812165-B2 | 6-substituted pyridoindolone derivatives, production and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-10-12 | — | — | US | claimed |
| EP-1742947-B1 | 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-08-20 | — | — | EP | claimed |
| US-20070129365-A1 | 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-06-07 | — | — | US | claimed |
| US-7812165-B2 | 6-substituted pyridoindolone derivatives, production and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-10-12 | — | — | US | disclosed |
| US-20070129365-A1 | 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129365-A1 | 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof | PNPO, CYP2D6, DPYD | CYP2C19 72/4885DNM2 3298/4885CSNK2A2 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.